14/06/18 - Val401 update3 Mar 2019 07:55
A
London, UK., 14 June 2018: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company, is pleased to provide an update on the VAL401 commercial development.
The VAL401 clinical trial and data collection is now complete and the regulatory process is moving towards completion with the Clinical Study Report on schedule for submission within the regulatory timeframe of two years from trial approval (July 2018). These current and future development updates now focus on the commercial aspects of the completed science development.
Since the results were released from the VAL401 trial on 16 January 2018, the development has focussed on commercial areas.  An advisory board of UK Key Opinion Leaders was consulted, addressing the significance of the results obtained and the positioning of VAL401 in the UK and global market. Advanced conversations have continued with a number of prospective partners with the aim of achieving a partnership, to progress the project appropriately towards eventual patient use. Further validation of the project is demonstrated by the approval of a second patent in New Zealand - further details re set out below.
Â
Advisory board of UK Key Opinion Leaders ("Advisory Board")
An Advisory board consisting of members of the patient advocate, hospital and consultant community, all with specialisms in oncology and particularly in end-of-life care in cancer patients was convened to discuss the results and impact of VAL401. The meeting was organised and executed by the independent communications company, Hayward Medical, who provided a report detailing the ideas and enthusiasm the participants showed for the development of VAL401 to date. In particular the need for a treatment that can be used to alleviate symptoms even in end-stage patients was highlighted and that the co-prescription of a drug to provide supportive benefits in addition to anti-cancer benefits would be valuable from the beginning of the patient journey, alongside currently used approaches.
The participants' individual comments included that they would be confident taking VAL401 immediately on cancer diagnosis, alongside standard of care treatment; that every month of additional life secured is priceless, particularly with maintained quality, and in fact that, terminal patients often prefer to retain their Quality of Life than to risk further disruptive treatments.
Â
2018 BIO International Convention
Dr Dilly attended the BIO International Convention in Boston during the week of 4 June 2018. Recognised as the largest partnering and exhibition event in the industry, BIO is an opportunity to access global biotech and pharma companies. Presenting the VAL401 project, Dr Dilly held meetings to progress commercial conversations further with current and future partners, as well as presenting the project to new audiences.
Notification of Acceptance re Second New Zealand patent
ValiSeek has received notification that a furth
Sign In
Follow the stocks
